# Biologics Market

> Biologics Market Research Report: Size, Share, Trend Analysis By Product Type (Monoclonal Antibodies, Vaccines, Cell and Gene Therapy, Recombinant Proteins, Hormones), By Applications (Oncology, Infectious Diseases, Autoimmune Disorders, Cardiovascular Diseases, Neurological Disorders), By End Users (Hospitals, Pharmaceutical Companies, Research Institutes, Diagnostics Laboratories), By Source (Microbial, Mammalian, Plant, Transgenic Animals) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 16.6%
- **2024:** $ 616.25 Billion
- **2025:** $ 718.56 Billion
- **2035:** $ 3,338.29 Billion
- **Key Players:** Companies such as AbbVie (US), Amgen (US), Roche (CH), Johnson & Johnson (US), Novartis (CH), Bristol-Myers Squibb (US), Sanofi (FR), Gilead Sciences (US), Merck & Co. (US) are some of the major participants in the market.

**Report ID:** MRFR/HC/0831-CR · **Pages:** 138 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** July 09, 2026

**URL:** https://www.marketresearchfuture.com/reports/biologics-market-1339

---

## Market Summary

Biologics Market size was valued at USD 616.25 Billion in 2024, and the market is projected to grow from USD 718.56 Billion in 2025 to USD 3,338.29 Billion by 2035, registering a CAGR of 16% during the forecast period 2025–2035. North America led the market in 2024 with over 45.08% share, generating around USD 277.8 Billion in revenue.
 
The Biologics Market is primarily driven by the rising prevalence of chronic diseases and increasing demand for targeted therapies. Continuous advancements in biotechnology, expanding biologic drug pipelines, and growing investments in precision medicine are accelerating biologics adoption across oncology, autoimmune, and rare disease treatment worldwide.
 
According to the WHO, noncommunicable diseases (NCDs) account for approximately 43 million deaths annually, representing nearly 75% of all global deaths. Cardiovascular diseases cause around 17.9 million deaths, cancers 9.3 million, chronic respiratory diseases 4.1 million, and diabetes over 2 million deaths each year. This growing chronic disease burden continues to strengthen demand for advanced biologic therapies that provide targeted and long-term disease management.

## Market Drivers

### Advancements in Biotechnology

Technological innovations in biotechnology are significantly influencing the Biologics Industry. The development of novel bioprocessing techniques and advanced analytical methods has enhanced the efficiency and effectiveness of biologic drug production. For instance, the introduction of continuous manufacturing processes has the potential to reduce production costs and time, thereby making biologics more accessible.
 
Furthermore, advancements in gene editing technologies, such as CRISPR, are paving the way for the creation of more precise biologic therapies. This evolution in biotechnology not only supports the growth of the market but also encourages investment in research and development, as companies seek to capitalize on these emerging technologies.
 

- According to the World Bank, global current health expenditure exceeds 9% of global GDP, reflecting sustained investment in healthcare innovation and biotechnology infrastructure. Growing funding for advanced bioprocessing, genomics, and precision medicine supports the development of next-generation biologics, enabling pharmaceutical companies to accelerate innovation while improving manufacturing efficiency and treatment outcomes.

### Regulatory Support for Biologics

Regulatory agencies are increasingly recognizing the importance of biologics in modern medicine, which appears to be fostering a more favorable environment for the Biologics Industry. Streamlined approval processes and guidelines for [biosimilars](https://www.marketresearchfuture.com/reports/biosimilars-market-1329) are encouraging manufacturers to invest in biologic drug development.
 
For example, the introduction of the Biosimilar User Fee Act has facilitated the review and approval of biosimilars, thereby expanding treatment options for patients. This regulatory support is likely to enhance competition within the market, leading to lower prices and improved access to biologic therapies. As regulations continue to evolve, the market may witness a surge in the introduction of innovative biologic products.
 

- According to PubMed, regulatory harmonization and streamlined biosimilar approval pathways have significantly improved biologic accessibility worldwide. Numerous peer-reviewed studies demonstrate that approved biosimilars achieve comparable efficacy, safety, and immunogenicity to reference biologics, encouraging broader clinical adoption while supporting regulatory confidence and expanding patient access to cost-effective biologic therapies.

### Rising Demand for Targeted Therapies

The increasing demand for targeted therapies is driving growth in the Biologics Industry. Patients and healthcare providers are seeking more effective treatment options that minimize side effects and improve therapeutic outcomes. market, which are designed to target specific pathways and mechanisms of disease, are well-positioned to meet this demand.
 
Market analysis indicates that the targeted therapy segment is expected to grow significantly, with biologics playing a central role in this expansion. This shift towards personalized medicine is likely to enhance the appeal of biologics, as they offer tailored treatment solutions. Consequently, the market is poised for continued growth as the focus on targeted therapies intensifies.

### Increasing Prevalence of Chronic Diseases

The rising incidence of chronic diseases such as diabetes, cancer, and autoimmune disorders appears to be a primary driver for the Biologics Industry. As these conditions become more prevalent, the demand for biologic therapies, which offer targeted treatment options, is likely to increase. According to recent data, biologics accounted for approximately 40% of the total pharmaceutical market, reflecting their growing importance in disease management.
 
This trend suggests that healthcare providers are increasingly turning to biologics as a viable alternative to traditional therapies, thereby propelling the market forward. The market is expected to continue expanding as more innovative biologic drugs are developed to address these chronic conditions, potentially improving patient outcomes and quality of life.

### Growing Investment in Biopharmaceutical Research

The increasing investment in biopharmaceutical research and development is a crucial driver for the Biologics Industry. Pharmaceutical companies are allocating substantial resources to discover and develop new biologic therapies, reflecting a shift in focus towards biologics as a key component of their portfolios.
 
Recent statistics indicate that biopharmaceutical R&D spending has reached unprecedented levels, with billions of dollars being invested annually. This trend suggests that the industry is prioritizing biologics due to their potential for high returns and the ability to address unmet medical needs. As investment continues to flow into the market, it is likely to stimulate innovation and accelerate the development of new therapies.

## Future Outlook

The Biologics Market size is projected to reach USD 3,338.29 Billion by 2035, growing at a CAGR of 16.6%, driven by advancements in biotechnology, increasing chronic diseases, and rising healthcare expenditures. Annual biologics sales now account for a significant portion of the total revenue generated by the global pharmaceutical industry. High demand for monoclonal antibodies and vaccines drives the steady financial performance of this sector. Strong market growth is sustained by an aging global population and the rising prevalence of metabolic disorders

**New opportunities:**

- Development of personalized biologics targeting specific patient demographics. Expansion of biosimilars to enhance market accessibility and affordability. Investment in automated biologics manufacturing technologies to improve efficiency.

By 2035, the Biologics Market is expected to be robust, driven by innovation and strategic investments.

## Segment Insights

### By Type: Monoclonal Antibodies (Largest) vs. Cell and Gene Therapy (Fastest-Growing)

In the Biologics Market, Monoclonal Antibodies lead the segment with a significant 48% market share due to their widespread applications in oncology, immunology, and chronic diseases. This dominance is driven by the increasing prevalence of target-specific therapies and the rising number of approved monoclonal antibodies. In contrast, Cell and Gene Therapy represents an emerging segment showcasing rapid growth, propelled by advancements in genetic engineering and personalized medicine. The focus on innovative treatment options for previously incurable conditions is driving interest and investment in this area. The market dynamics for Cell and Gene Therapy are fueled by technological advancements and a better understanding of the immune system. These therapies offer the potential for one-time treatments that can fundamentally alter disease outcomes, attracting significant investment from pharmaceutical companies. The competitive landscape is evolving as more players enter this space, aiming to leverage these advanced technologies to meet unmet medical needs, thus contributing to its designation as the fastest-growing segment in the Biologics Market.

Johnson & Johnson continues strengthening its biologics portfolio through innovative monoclonal antibody therapies across immunology and oncology. In 2024, the company invested over USD 17 billion in research and development, supporting next-generation antibody innovation, expanded clinical programs, and improved patient outcomes, reinforcing monoclonal antibodies as the leading biologics segment.

### By Application: Oncology (Largest) vs. Infectious Diseases (Fastest-Growing)

In the Biologics Market, the Application segment is significantly dominated by Oncology, which holds the largest share of 51% due to the rising incidence of cancer and the increasing demand for targeted therapies. Following closely are Infectious Diseases, Autoimmune Disorders, Cardiovascular Diseases, and Neurological Disorders, each contributing to the diversity of this market. Autoimmune Disorders and Cardiovascular Diseases have shown considerable shares as well, while the growth of Neurological Disorders reflects the emerging focus on brain-related treatments.

Novartis continues expanding its oncology biologics pipeline through targeted therapies and immuno-oncology innovations. The company maintains hundreds of active clinical studies globally, supported by continuous regulatory approvals and strategic research investments. These advancements strengthen biologics adoption in cancer treatment, reinforcing oncology as the largest application segment in the global biologics market.

### By End User: Hospitals (Largest) vs. Pharmaceutical Companies (Fastest-Growing)

The biologics market shows a diverse distribution among various end users, with hospitals taking the lead as the largest segment with market share of 57%. This dominance is due to their vital role in the administration of biologics to patients. Pharmaceutical companies follow closely, leveraging their capabilities to innovate and commercialize biologic drugs, significantly contributing to market dynamics. Research institutes and diagnostics laboratories play pivotal roles as well, although their shares are comparatively smaller, focusing more on research and development and diagnostic testing respectively.

Bristol Myers Squibb continues collaborating with leading hospital networks to improve access to advanced biologic therapies for oncology, hematology, and immunology patients. The company's expanding biologics portfolio and continued investment in hospital-based treatment programs support increasing biologic utilization, strengthening hospitals as the dominant end-user segment within the biologics market.

### By Source: Mammalian (Largest) vs. Microbial (Fastest-Growing)

The Biologics Market is segmented into four main sources: microbial, mammalian, plant, and transgenic animals. Among these, mammalian sources hold the largest market share due to their ability to produce complex proteins that closely mimic human biology. Microbial sources, although smaller in market share, are showing significant potential for growth, driven by advancements in biotechnology and an increasing demand for sustainable production methods. Growth trends within the source segment indicate a shift towards microbial and plant-based sources. The rise in biopharmaceuticals produced from microbial systems is significantly contributing to the growth of the segment. Additionally, plant-based production systems are becoming more recognized for their potential to reduce costs and improve scalability, further propelling this segment's growth in the coming years.

Sanofi continues investing in mammalian cell culture technologies to support large-scale biologics manufacturing across vaccines, immunology, and rare diseases. The company's advanced biomanufacturing facilities and continuous process optimization improve production efficiency, product quality, and commercial scalability, reinforcing mammalian expression systems as the preferred source for complex biologic therapeutics.

## Regional Market Share Analysis

### North America: Biologics Market Innovation Leader

North America accounted for the largest share of the global market size, reaching USD 277.8 billion in 2024. The region benefits from advanced healthcare infrastructure, significant R&D investments, and a strong regulatory framework that fosters innovation. The increasing prevalence of chronic diseases and the growing demand for personalized medicine are key drivers of market growth. The sector for biologics US remains a global leader in innovation due to robust investment and a favorable regulatory environment.

- According to the CDC, approximately 129 million U.S. adults are living with at least one major chronic disease, including cancer, diabetes, cardiovascular disease, or hypertension. The growing burden of chronic illnesses continues to increase demand for biologic therapies, while the region's advanced healthcare infrastructure and strong reimbursement environment support sustained market expansion.

The competitive landscape is characterized by continuous innovation and strategic collaborations among key players. Canada also contributes significantly to the market, focusing on biosimilars and novel therapies. The presence of robust healthcare systems and supportive government policies further strengthens the market position of North America.

- Gilead Sciences continues strengthening North America's biologics ecosystem through significant investments in cell therapy, oncology, and immunology. The company invested approximately USD 5.9 billion in R&D during 2024, advancing innovative biologic therapies and expanding clinical development programs. Continuous innovation and strategic investments reinforce the region's leadership in biologics research and commercialization.

### Europe: Regulatory Framework and Growth

Europe market size was valued at USD 184.875 billion in 2024, making it the second-largest regional market with a 30% share. The region is characterized by a strong regulatory framework that encourages innovation and ensures patient safety. The European Medicines Agency (EMA) plays a pivotal role in the approval process, facilitating the entry of new biologics into the market. The increasing demand for advanced therapies and the rise of chronic diseases are significant growth drivers in this region.

Leading countries in Europe include Germany, France, and the United Kingdom, which are home to several key players like Roche and Sanofi. The competitive landscape is marked by a mix of established companies and emerging biotech firms, fostering a dynamic environment for innovation. Collaborative efforts between public and private sectors are enhancing research capabilities, further solidifying Europe's position in The market.

- The European Medicines Agency (EMA) has authorized more than 100 biosimilar medicines across multiple therapeutic areas, making Europe one of the world's most mature biologics and biosimilars markets. The well-established regulatory framework accelerates patient access to innovative biologics, supports competitive pricing, and encourages continuous pharmaceutical innovation, strengthening Europe's position as the second-largest regional market.

### Asia-Pacific : Rapidly Growing Biologics Market

Asia-Pacific is witnessing rapid growth in the market, accounting for approximately 20% of the global share. The region's growth is driven by increasing healthcare expenditure, a rising population, and a growing prevalence of chronic diseases. Countries like China and India are at the forefront, supported by government initiatives aimed at enhancing healthcare access and affordability.

The regulatory environment is evolving, with agencies working to streamline the approval process for biologics. China is the largest market in the region, with significant investments in biotechnology and a focus on biosimilars. India is also emerging as a key player, with a growing number of biotech firms entering the market. The competitive landscape is characterized by both local and international companies, including major players like Gilead Sciences and Merck & Co. The increasing collaboration between academia and industry is expected to drive further innovation in the region.

### Middle East and Africa : Untapped Potential in Biologics Market

The Middle East and Africa represent an emerging market for biologics, currently holding about 5% of the global share. The region is characterized by a growing interest in advanced therapies, driven by increasing healthcare investments and a rising burden of chronic diseases. Governments are focusing on improving healthcare infrastructure and regulatory frameworks to attract foreign investments in the biopharmaceutical sector. The demand for biologics is expected to rise as healthcare systems evolve and access to treatments improves.

Leading countries in this region include South Africa and the UAE, where there is a growing presence of both local and international biotech firms. The competitive landscape is still developing, with opportunities for growth in biosimilars and innovative therapies. Collaborations between governments and private sectors are essential for fostering a conducive environment for the market to thrive in the Middle East and Africa.

## Competitive Benchmarking

The Biologics Market is characterized by a dynamic competitive landscape, driven by innovation, strategic partnerships, and a focus on personalized medicine. Major players such as AbbVie (US), Amgen (US), and Roche (CH) are at the forefront, leveraging their extensive research capabilities and robust product pipelines to maintain competitive advantages. AbbVie (US) emphasizes its commitment to immunology and oncology, while Amgen (US) focuses on expanding its biosimilars portfolio. Roche (CH), with its strong emphasis on diagnostics and targeted therapies, positions itself as a leader in precision medicine.
 
Collectively, these strategies not only enhance their market presence but also contribute to a rapidly evolving competitive environment where differentiation is increasingly based on technological advancements and therapeutic innovations. Key business tactics within the market include localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness. The market structure appears moderately fragmented, with a mix of established players and emerging biotech firms.
 
This fragmentation allows for diverse approaches to product development and market entry, fostering a competitive atmosphere where innovation is paramount. The collective influence of key players shapes market dynamics, as they engage in strategic collaborations and investments to bolster their capabilities and expand their reach. In August 2025, AbbVie (US) announced a strategic partnership with a leading gene therapy company to develop innovative treatments for rare genetic disorders. This collaboration is poised to enhance AbbVie's capabilities in [gene editing](https://www.marketresearchfuture.com/reports/gene-editing-market-707) and expand its therapeutic offerings, reflecting a broader trend towards personalized medicine.
 
The strategic importance of this partnership lies in its potential to accelerate the development of groundbreaking therapies, thereby positioning AbbVie as a frontrunner in the evolving landscape of biologics. In September 2025, Amgen (US) launched a new biosimilar product aimed at increasing access to biologic therapies for patients with chronic conditions. This move not only underscores Amgen's commitment to affordability but also highlights its strategic focus on expanding its biosimilars portfolio.
 
The introduction of this product is likely to enhance Amgen's competitive positioning, as it addresses the growing demand for cost-effective treatment options in the biologics sector. In July 2025, Roche (CH) unveiled a new digital platform designed to streamline clinical trial processes and enhance patient engagement. This initiative reflects Roche's commitment to integrating digital technologies into its operations, thereby improving efficiency and accelerating the development of new therapies. The strategic significance of this digital transformation lies in its potential to enhance Roche's competitive edge by enabling faster and more effective clinical trials, ultimately leading to quicker market access for innovative treatments.
 
As of October 2025, current competitive trends in the market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances are shaping the landscape, as companies collaborate to leverage complementary strengths and drive innovation. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition towards a focus on technological advancements, innovative therapies, and reliable supply chains. This shift underscores the importance of agility and adaptability in navigating the complexities of the market.

## Recent News & Developments

- A recent biologics market report highlights the shift toward decentralized clinical trials and AI-driven drug discovery. These documents serve as vital roadmaps for investors looking to understand the risks and rewards of the biotech landscape. Major pharmaceutical players are aggressively defending their market share through strategic acquisitions and pipeline diversification. Meanwhile, emerging biotech startups are capturing niche segments by focusing on rare orphan diseases.
- **Q3 2025: Eli Lilly to Acquire Morphic Holding for $3.2 Billion to Expand Biologics Market Pipeline** Eli Lilly announced a definitive agreement to acquire Morphic Holding, a biotechnology company focused on oral integrin therapies, for $3.2 billion in cash, strengthening Lilly’s biologics and immunology portfolio.
- **Q2 2025: Sanofi Opens New market Manufacturing Facility in France** Sanofi inaugurated a state-of-the-art biologics manufacturing plant in Vitry-sur-Seine, France, aimed at increasing production capacity for monoclonal antibodies and other biologic drugs.
- **Q2 2025: Amgen Receives FDA Approval for BLINCYTO® (blinatumomab) for Additional Indication** Amgen announced that the U.S. FDA approved BLINCYTO® for the treatment of adults with newly diagnosed B-cell precursor acute lymphoblastic leukemia, expanding the drug’s approved uses.
- **Q2 2025: Samsung market Signs $1 Billion Manufacturing Contract with AstraZeneca** Samsung market secured a $1 billion contract to manufacture biologic drugs for AstraZeneca, further cementing its role as a leading contract development and manufacturing organization (CDMO) in the biologics sector.
- **Q1 2025: Roche Appoints New Head of market Division** Roche announced the appointment of Dr. Maria Fernandez as the new Head of its market Division, effective March 2025, to drive innovation and growth in its biologics business.
- **Q1 2025: Regeneron and Intellia Therapeutics Announce Strategic Collaboration for CRISPR-based market** Regeneron and Intellia Therapeutics entered a multi-year collaboration to develop CRISPR-based biologic therapies for genetic diseases, combining Regeneron’s biologics expertise with Intellia’s gene editing technology.
- **Q4 2024: Pfizer Launches New Biosimilar for Oncology in the U.S.** Pfizer announced the U.S. launch of a new biosimilar to treat certain types of cancer, expanding its biologics portfolio and increasing competition in the oncology biosimilars market.
- **Q4 2024: Bristol Myers Squibb Receives EMA Approval for New [Biologic Therapy](https://www.marketresearchfuture.com/reports/biologic-therapy-market-840) for Multiple Sclerosis** Bristol Myers Squibb received European Medicines Agency (EMA) approval for its new biologic therapy targeting relapsing forms of multiple sclerosis, marking a significant regulatory milestone.
- **Q4 2024: Novo Nordisk to Invest $2.3 Billion in New market Plant in Denmark** Novo Nordisk announced a $2.3 billion investment to build a new biologics manufacturing facility in Denmark, aimed at meeting growing global demand for its diabetes and obesity biologics.
- **Q3 2024: AbbVie and Genmab Announce FDA Approval of Epkinly™ for Diffuse Large B-cell Lymphoma** AbbVie and Genmab received FDA approval for Epkinly™, a new biologic therapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma, expanding treatment options for patients.
- **Q3 2024: GSK Acquires Biotech Startup Affinivax for $2.1 Billion to Boost Vaccine market Portfolio** GSK completed the acquisition of Affinivax, a biotech company specializing in next-generation vaccine biologics, for $2.1 billion, strengthening its pipeline in infectious disease prevention.
- **Q2 2024: Moderna Announces $500 Million Investment in New mRNA market Facility in Canada** Moderna revealed plans to invest $500 million in a new mRNA biologics manufacturing facility in Quebec, Canada, to support the production of vaccines and therapeutics for global markets.

## Report Scope

| MARKET SIZE 2024 | 616.25(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 718.56(USD Billion) |
| MARKET SIZE 2035 | 3338.29(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 16.6% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | AbbVie (US), Amgen (US), Roche (CH), Johnson & Johnson (US), Novartis (CH), Bristol-Myers Squibb (US), Sanofi (FR), Gilead Sciences (US), Merck & Co. (US) |
| Segments Covered | Product Type, Applications, End Users, Source, Regional |
| Key Market Opportunities | Advancements in personalized medicine and biologics manufacturing technologies drive growth in the Biologics Market. |
| Key Market Dynamics | Rising demand for personalized medicine drives innovation and competition in the biologics market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current valuation of the Biologics Market as of 2024?**
A: The overall market valuation of the Biologics Market was 616.25 USD Billion in 2024.

**Q: What is the projected market size for the Biologics Market in 2035?**
A: The projected valuation for the Biologics Market in 2035 is 3338.29 USD Billion.

**Q: What is the expected CAGR for the Biologics Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the Biologics Market during the forecast period 2025 - 2035 is 16.6%.

**Q: Which segment of the Biologics Market had the highest valuation in 2024?**
A: In 2024, the Monoclonal Antibodies segment had the highest valuation at 200.0 USD Billion.

**Q: What are the key applications driving growth in the Biologics Market?**
A: Key applications driving growth include Oncology, Neurological Disorders, and Autoimmune Disorders, with valuations reaching 123.25 USD Billion, 269.5 USD Billion, and 75.0 USD Billion respectively in 2024.

**Q: Which end user segment is projected to dominate the Biologics Market by 2035?**
A: By 2035, Pharmaceutical Companies are projected to dominate the Biologics Market, with a potential valuation of 1300.0 USD Billion.

**Q: What is the valuation range for Cell and Gene Therapy in the Biologics Market?**
A: The valuation range for Cell and Gene Therapy in the Biologics Market is from 100.0 USD Billion to 600.0 USD Billion.

**Q: How do the key players in the Biologics Market influence its growth?**
A: Key players such as AbbVie, Amgen, and Roche likely influence the Biologics Market's growth through innovation and strategic partnerships.

**Q: What is the valuation of the Recombinant Proteins segment in 2024?**
A: The Recombinant Proteins segment was valued at 150.0 USD Billion in 2024.

**Q: Which source type is expected to show significant growth in the Biologics Market?**
A: Mammalian sources are expected to show significant growth, with a valuation range of 246.5 USD Billion to 1300.0 USD Billion.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/biologics-market-1339*